In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its highest yearly gains since the Covid-19 pandemic. Meanwhile, a combination of increased visibility and solid market performance has led to a more favorable climate.
Speaking to Investing News Network, Eric Shrayer, director of research at Reynders, McVeigh Capital Management, stated that the most notable development for the life science and biotech sectors in 2025 so far has been the $47 billion NIH budget. According to Shrayer, raising funds is often the most difficult barrier for small biotech companies, especially in a low-growth environment characterized by higher interest rates and stricter capital markets.
In another vein, biotech stocks have seen an increase in M&A activity. In March alone, there were ten acquisitions valued at around $31.5 billion. The approaching patent cliff, which some predict could cost the industry $300 billion by 2030, appears to be a major driver of this activity.
Our Methodology
For this list, we used stock screeners to identify profitable biotechnology stocks with the highest TTM net income and net income margins. These stocks are widely held by hedge funds and followed by analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ranks among the most profitable biotech stocks to buy now. On March 25, BofA Securities raised ACADIA Pharmaceuticals Inc. to Buy from Neutral, retaining a $29 price objective. The firm stated that the nearly 25% drop in the share price recently was due to year-to-date macroeconomic factors rather than fundamentals.
The firm stated that consistent Nuplazid sales in Parkinson’s psychosis give protection against future decline. BofA Securities estimates $888 million in peak sales in 2029, which may be modest, given recent field force investments that could boost growth.
According to BofA Securities, ACADIA Pharmaceuticals Inc. estimates that its pipeline has a $11 billion opportunity, which is currently discounted and may offer upside. The firm added that phase 2 data for remlifanserin in Alzheimer’s psychosis is anticipated in August–October and is partially de-risked based on previous Nuplazid psychosis basket trial results. The firm forecasts $2.1 billion in nominal peak sales for 2038, with a 40% chance of success in Alzheimer’s psychosis.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. It targets unmet medical needs in areas such as Parkinson’s disease, psychosis, schizophrenia, and rare neurological conditions.
9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc.. The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, and Phesgo.
Halozyme Therapeutics, Inc. began to disclose the royalties from these three medications during the past quarter. TD Cowen stated that Vyvgart Hytrulo is a more significant contributor than previously assumed, which reduces the risk of near-term royalty increase, assuming the ongoing success across numerous indications.
Similarly, following a collaboration announcement, Leerink Partners reiterated its Market Perform stock rating and $83 price target for Halozyme Therapeutics, Inc.. Halozyme has established an affiliation with Vertex Pharmaceuticals on the Hypercon technology platform.
Compared with Halozyme’s ENHANZE platform, the Hypercon technology enables higher drug concentrations, making at-home treatment possible. In addition to possible future milestone payments and royalties, Vertex will reimburse Halozyme $15 million in advance.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company that creates, manufactures, and sells drug-device combination solutions using advanced auto-injector technologies.
8. Argenx SE (NASDAQ:ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE, citing a quarterly monitoring poll that indicated first-quarter sales could outperform consensus projections. The firm’s fifth quarterly study of 30 neurologists treating patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy revealed persistent interest in the Vyvgart brand.
According to TD Cowen, Vyvgart’s first-quarter revenues will exceed the consensus expectation of $1,271 million, which is a 1% decrease from the previous quarter. The firm ascribed the predicted increase to the adoption of the Vyvgart Hytrulo prefilled syringe formulation.
According to the aforesaid study, the prefilled syringe formulation, which is still being used in both generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy diagnosis, was notably favored.
TD Cowen also voiced optimism about possible launches in ocular myasthenia gravis, for which a submission is expected shortly, and seronegative myasthenia gravis, which has a regulatory judgment date of May 10.
Argenx SE is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
7. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitinib could be administered in the early stages of hidradenitis suppurativa, rather than as a post-biologic oral alternative.
H.C. Wainwright mentioned a meeting with a hidradenitis suppurativa expert who oversees a clinic at Geisinger Health with about 700 patients rotating each year, with nearly 80% categorized as moderate to severe.
In a similar vein, Citizens JMP reaffirmed its Market Perform rating for Incyte Corporation following the presentation of revised clinical trial data at the AAD 2026 Congress. Incyte reported 54-week results from the Phase 3 STOP-HS1/HS2 studies, which evaluated povorcitinib in moderate-to-severe hidradenitis suppurativa.
The data demonstrated that effectiveness deepens gradually with increasing HiSCR50 rates in both the initial treatment and crossover groups. Citizens stated that it has grown more convinced that implementation across the current portfolio can overcome the $3 billion-plus ruxolitinib patent gap by the end of 2028.
Incyte Corporation, an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.
6. Genmab A/S (NASDAQ:GMAB)
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical triggers anticipated in 2026, the firm sees the current price dip following a loss in a confirmatory DLBCL study as a purchasing opportunity.
According to the firm, Genmab’s Epkinly is expected to bring in $3.4 billion in peak sales, with the frontline trial EPCORE DLBCL-2 being the main value engine for the asset. Similarly, Rina-S could generate $2.5 billion in peak sales spanning many indications, with Wolfe anticipating findings from the RAINFOL-01 PROC this year.
Also, with regard to sales, Genmab A/S reported that DARZALEX’s global net sales amounted to $3.964 billion in Q1 2026. The sales data include cancer treatment formulas administered intravenously and subcutaneously. Net sales in the US totaled $2.208 billion, with international markets generating $1.756 billion in revenue.
Genmab A/S is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
5. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc.’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher dosage, monotherapy WVE-007 produced weight and fat reduction measures that fell short of investor expectations.
Arrowhead Pharmaceuticals Inc. stated that research is being done to provide hypotheses regarding the optimal locations for INHBE and ALK7 inhibition. In order to further assess this prospect, the company expanded the INHBE studies in response to promising signals in patients with Type 2 diabetes and in combination with tirzepatide, following data disclosed in January.
According to TD Cowen, these methods are most likely to be used in maintenance and supplementary settings, or in other specific indications such as MASH and Type 2 diabetes. The firm stated that it anticipates more information in the latter part of the year, including closely watched sHTG data in the third quarter.
Arrowhead Pharmaceuticals Inc. develops medicines for the treatment of intractable diseases in the US. Its pipeline primarily includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.
4. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) ranks among the most profitable biotech stocks to buy now. At the Society of Gynecologic Oncology Annual Meeting on April 10, Corcept Therapeutics Incorporated reported the conclusive total survival results from its Phase 3 ROSELLA study of Lifyorli in combination with nab-paclitaxel for platinum-resistant ovarian cancer.
The FDA had approved Lifyorli for the treatment of individuals with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had up to three prior systemic therapies, at least one of which included bevacizumab.
Based on the results of the study, patients who received Lifyorli in addition to nab-paclitaxel had a 35% lower risk of dying than those who only received nab-paclitaxel. Additionally, compared to nab-paclitaxel monotherapy, the combination showed a 30% lower risk of disease progression.
Following FDA approval, Wolfe Research boosted Corcept Therapeutics Incorporated to Peerperform from Underperform. The firm sees the approval as eliminating a key downside prospect for the stock. Nonetheless, Wolfe questions the long-term viability of Corcept’s main Cushing’s disease franchise.
Corcept Therapeutics Incorporated, incorporated in 1998, is a California-based biopharmaceutical company that discovers and develops solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders.
3. PTC Therapeutics, Inc. (NASDAQ:PTCT)
PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics, Inc. announced positive outcomes from a 24-month interim assessment of its PIVOT-HD extension trial, which assessed votoplam for the treatment of Huntington’s disease. The trial found dose-dependent improvements in disease progression in people with Stage 2 Huntington’s disease.
According to the Composite Unified Huntington’s Disease Rating Scale, patients on the 10 mg dose showed a 52% slowdown in disease progression compared to a natural history sample, whilst those on the 5 mg dose exhibited a 28% slowdown.
Meanwhile, on April 9, Raymond James began coverage of PTC Therapeutics, Inc., with an Outperform rating and a $108 price target. The firm emphasized the introduction of Sephience, which is billed as the first and only Phenylketonuria medication that combines oral dose with phenylalanine management and diet adaptability.
Analyst Tiago Fauth noted that the therapy has merits over traditional standard-of-care therapies for the hereditary condition.
PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for rare genetic disorders.
2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc. with a $875 price target. The assessment followed an Integrated Oncology Day event at the Sylvester Cancer Center in Miami. The event included discussions on oncology therapies and ophthalmology with key experts from the Bascom Palmer Eye Institute.
One of the event’s main themes revolved around optimism about BCMA T-cell engagers transitioning into second-line treatment with MAJESTEC-3 results. Leading experts claimed they were not worried about sequencing CAR-T therapy following BCMA T-cell engagers.
Meanwhile, Cantor Fitzgerald maintained its Overweight rating and $800 price target for Regeneron Pharmaceuticals, Inc. on April 8. The firm predicted that near-term fianlimab data will continue to dominate first-quarter 2026 findings.
Cantor Fitzgerald isn’t expecting data before the Q1 2026 earnings call. For the quarter, the firm expects a lower-impact print, led by a broadly in-line and well-anticipated Eylea HD result and a minor shortfall for Dupixent in what it calls the notoriously difficult first quarter.
Regeneron Pharmaceuticals, Inc. is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.
1. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, Bank of America reiterated Vertex Pharmaceuticals Incorporated as a top large-cap biotech pick for 2026, with a $598 price objective. The firm stated the company’s cystic fibrosis franchise has the ability to generate cash flow to support pipeline growth. BofA also cited the rare kidney disease franchise as a major long-term growth engine, citing encouraging results for povetacicept in IgA nephropathy.
In a similar vein, Argus boosted Vertex’s price target to $520 on March 19, highlighting the improved performance of its cystic fibrosis brand, especially triple-combination medicines like Trikafta/Kaftrio and the expanding Alyftrek regimen.
The ratings come around a timeline where the United States Food and Drug Administration approved Vertex Pharmaceuticals’ expanded use of ALYFTREK for treating patients with cystic fibrosis aged 6 and up. The label extension was backed up by clinical and/or in vitro results from 564 variants responding to ALYFTREK and 521 variants responding to TRIKAFTA.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.
Hedge Fund Resource Center